strategic review out , page-9

"The big pharmas make so much money out of the common cold and asthma sufferers. Maybe they joined together to boycott Vapanmivir. "

Muzza, I agree with you on the above. Big pharmas, especially GSK, hate to see Vapendavir to hit the market. They ate trying to "starve" Biota.

This shift of the focus is a good strategvy to grow the company. The next biggest task for the current management to do is the Lani trials and setting up sales force for government orders and whole salers.

Only With a stable and regular revenue, Can biota more confidently push its other discovered drug pipelines to late stages and even to the market.

The pervious management under PC leadership sucks.

My opinions only.